(Reuters) - LONDON, April 11 - A keenly awaited U.S. panel hearing on Merck & Co. Inc.'s pain reliever Arcoxia will be important also for Swiss rival Novartis AG , according to industry analysts.
More than two years after Merck was forced to pull Vioxx from the market because of cardiovascular side effects, both firms are trying to get newer drugs in the same Cox-2 inhibitor class approved in the United States.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment